Meropenem-Pralubactam

Phase 1Small molecule

Qilu Pharmaceutical Co., Ltd.

Meropenem-Pralubactam is one of 14 small molecule programs targeting Concentration. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConcentrationRecruiting

ConcentrationPhase 1

Recruiting

Competition

Competitive Landscape

17 competitors in Concentration

#DrugCompanyPhaseTrials

Vibativ

AApotex Inc.

Approved

1 2

Wilate

Octapharma

Phase 3

1 3

Xyrem

Jazz Pharmaceuticals

Preclinical

1 4

Inhaled Nitric Oxide

LLee's Pharmaceutical Limited

Phase 1

1 5

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

3 6

Vfend

PPrism Pharmaceuticals

Preclinical

3 7

Zibotentan/dapagliflozin

AstraZeneca

Phase 1

1 8

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

1 9

Blood Redrawal

CCentre Hospitalier Universitaire, Amiens

Preclinical

1 10

Lipopolysaccharide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Concentration1 trial

Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT07124468·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meropenem-Pralubactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meropenem-Pralubactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meropenem-Pralubactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Qilu Pharmaceutical Co., Ltd.

Meropenem-Pralubactam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Concentration1 trial

References

Drug Info

Quick Facts

Related News